In this must-see market update, Larry Williams returns with timely stock market analysis, trading insights, and macroeconomic forecasts. Discover what’s next for the Federal Reserve, interest rates, and inflation — and how it could impact top stocks like Tesla (TSLA), Nvidia (NVDA), Apple (AAPL), and consumer staples (XLP).
This video originally premiered on May 27, 2025. Watch on StockCharts’ dedicated Larry Williams page!
Previously recorded videos from Larry are available at this link.
Larisa Sprott of Sprott Money and Argo shares her thoughts on the gold and silver markets, saying she sees the ‘smart money’ continuing to gravitate toward these metals.
In her view, price dips present a chance to get in at lower levels.
Securities Disclosure: I, Charlotte McLeod, hold no direct investment interest in any company mentioned in this article.
Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.
According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.
This condition affects more than 7 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but there are currently none that affect the underlying causes of this neurodegenerative disease.
Alzheimer’s disease therapies that have been approved by the US Food and Drug Administration (FDA) include: rivastigmine by Novartis (NYSE:NVS); galantamine, developed by Janssen, a division of Johnson & Johnson (NYSE:JNJ); donepezil by Pfizer (NYSE:PFE); and memantine by AbbVie (NYSE:ABBV).
Since there is no cure for Alzheimer’s disease, death is often the result for patients as the ailment causes brain deterioration. And unfortunately, Alzheimer’s disease is rising in prevalence — a report from Grand View Research suggests that the global Alzheimer’s disease treatment market will be worth a significant US$15.57 billion by 2030 as more patients need treatment, and as more investments are made in biomarkers for diagnosis and drug development.
Market cap: US$18.43 billion
Share price: US$125.81
The first NASDAQ-listed Alzheimer’s drug company on this list is Massachusetts-based Biogen, a pioneer in the field of neuroscience. The firm is focused on developing, manufacturing and marketing therapies aimed at treating serious neurological, neurodegenerative, autoimmune and rare diseases.
The global biotechnology firm’s research areas include Alzheimer’s disease and dementia. However, the launch of Biogen’s FDA-approved Alzheimer’s disease drug Aduhelm faced a lot of pushback in 2022, both from the market and from Congress, over what was viewed as a hasty fast-track approval process and exorbitant costs to patients.
Biogen gave it another go with Leqembi (lecanemab-irmb), its amyloid-beta monoclonal antibody for the treatment of Alzheimer’s disease, which the FDA approved in 2023 under its accelerated approval pathway. The drug was jointly developed by Biogen and Tokyo-based pharmaceutical company Eisai (OTC Pink:ESALF,TSE:4523). It is for patients with mild cognitive impairment or mild dementia, and is the first drug shown to slow the progression of Alzheimer’s disease to win FDA approval.
In January 2025, Leqembi received another FDA approval, this time for intravenous maintenance dosing for early-stage Alzheimer’s. Later, in April, the European Commission granted Leqembi Marketing Authorization in the EU for the treatment of mild early-stage Alzheimer’s disease.
That same month, the FDA granted fast track designation to Biogen’s investigational tau-targeting therapy BIIB080 for the treatment of Alzheimer’s.
Biogen’s earnings report for Q1 shows that first quarter global in-market sales of Leqembi reached approximately US$96 million, including US in-market sales of approximately US$52 million.
Market cap: US$3.68 billion
Share price: US$21.98
Acadia Pharmaceuticals specializes in neuroscience and neuro-rare diseases. The biotech’s product portfolio includes the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis, as well as the first and only approved drug in the United States and Canada for the treatment of Rett syndrome.
Acadia’s clinical-stage pipeline includes drug candidates targeting Prader-Willi syndrome and Alzheimer’s disease psychosis.
The company expects to enroll its final patient in its RADIANT Phase 2 study of ACP-204 in Alzheimer’s disease psychosis by early 2026 and release topline data in mid-2026.
According to the company, there are currently no approved treatments for hallucinations and delusions associated with Alzheimer’s disease psychosis.
Market cap: US$642.85 million
Share price: US$7.53
Anavex Life Sciences is a clinical-stage biopharmaceutical company developing treatments for neurodegenerative, neurodevelopmental and neuropsychiatric disorders, such as Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome and other central nervous system disorders.
Anavex’ lead drug candidate, Anavex 2-73 (blarcamesine), has successfully completed Phase 2a and a Phase 2b/3 clinical trials for Alzheimer’s disease.
In early January, the company announced positive topline safety and efficacy data from more than three years of continuous treatment with blarcamesine for early Alzheimer’s disease patients. Later that month, Anavex announced it had been issued a US patent for the treatment.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
American Rare Earths Limited (ARR:AU) has announced ARR advances permitting at Cowboy State Mine
Download the PDF here.
Challenger Gold Limited (ASX: CEL) (‘CEL’ or the ‘Company’) is pleased to announce it has entered into an Investment Protection Agreement (“IPA” or “the Agreement”) with the Government of Ecuador for its 100% owned El Guayabo Project (“El Guayabo” or “the Project”). Under the terms of the IPA, the Government of Ecuador has granted CEL legal protections including stability of the regulatory framework, resolution of disputes through international arbitration, and protection of CEL’s investment.
The IPA covers US$75 million in investment from CEL encompassing expenditures from CEL’s initial acquisition of the project in 2019 and expenditure incurred until the end of 2027. It has an initial term of 8 years and is renewable. Key incentives and protections under the IPA include:
Commenting on the Investment Protection Agreement, CEL Managing Director, Mr Kris Knauer, said
“The completion of the Investment Protection Agreement is a significant development for the Project..
The IPA provides certainty with respect to the legal framework governing the Project, including stable mining regulations and fiscal terms, and security of title and investment for the term of the agreement. Additionally, it provides protection from all forms of confiscation and a mechanism for international arbitration should there be any disputes related to the project.
The IPA is also timely given recent corporate action in Ecuador as we take steps to monetise our Ecuador assets following the significant resource upgrade from 4.5 million ounce1 to 9.1 million ounces1,2,3.‘
Click here for the full ASX Release
McLaren Minerals Limited (ASX: MML) (‘McLaren’ or ‘Company’), is pleased to provide a further update on the phase 1 Drill Program at its wholly owned McLaren Titanium Project in the western Eucla Basin, Western Australia. This update is driven by the completion of geological interpretation of all the drilling during this campaign, in the absence of laboratory results.
Highlights
McLaren Titanium Project
McLaren Mineral Sands Managing Director, Simon Finnis, commented:
“While we have not yet received any assays, phase 1 has delivered strong confidence to our team regarding this project. The most recent interpretation not only confirm the integrity of our geological model, but importantly, demonstrates the scale of the opportunity ahead. Defining substantial potential for mineralisation outside the current Resource boundary positions us well for future resource growth. We’ve also made solid ground operationally—drilling was completed on time, we’ve brought costs down, and we’re seeing strong local support. Taken together, these outcomes give us a great deal of confidence as we move toward the next phase of work and continue building long-term value for shareholders.”
Click here for the full ASX Release
In order to invest or trade successfully, you have to have conviction. Conviction does not equal stubbornness. It’s very important to remain objective and occasionally question your conviction and adjust your strategy from time to time if signals warrant it. But I cannot trade personally if I believe there’s a 50/50 chance the market is going higher. That doubt will resonate with each and every swing in the market. I’ll chase at the wrong time and get whipsawed out of positions.
Instead, I evaluate those signals that work best for me – the same signals that have allowed me go against the grain and call significant market tops and bottoms over the past 5-7 years. Few were saying it was time to be long in early April, but I was quite clear. Topping signals were just as evident to me earlier this year, leading me to tell EarningsBeats.com members that I was 100% cash at the end of January. The technical confirmation of a market top occurred on Friday, February 21st. I published my belief of that confirmed market top in this same blog – again rather clearly:
You can click on this headline and read the whole story, if you’d like. After letting EB.com members know that I was fully committed on the long side in early April, because of bullish market maker manipulation, I have continued to track that market maker manipulation. Through Friday, it’s still telling me the same thing – BUY US STOCKS!
Listen, we’ve seen a massive run higher off that early-April low and profit taking and pullbacks will occur. That cannot deter us and should not be misconstrued as distribution ahead of a major market decline. In fact, there are a lot of technicians and market analysts talking about the big selling that’s taken place over the past week and how that will lead to further selling ahead. I completely disagree with this crew. We’ve seen almost zero selling or distribution in recent days. What we’ve seen are more gap downs, just like the ones that occurred after the March 13th low. Those opening and early morning selloffs saw subsequent buying throughout trading sessions. Check out the accumulation/distribution indicator on both the S&P 500 and NASDAQ 100 below:
S&P 500
You can see the AD line take a bit of a hit during the true period of distribution in 2025. Currently, however, the AD line is very near its all-time high. Last week (since Monday’s close), the SPY lost 15.74, falling from 594.85 to Friday’s close at 579.11. That was roughly a 2.5% pullback, but here’s what’s interesting. The SPY had gap downs the past four trading days that totaled 13.65. Nearly all of last week’s drop occurred at the opening bell. There was little selling during the trading day. We track this manipulative behavior in our “2025 Key Stocks Manipulation” excel spreadsheet, which we update for our members every Monday morning, so our members can clearly see the manipulation taking place on the SPY, QQQ, IWM, and 11 individual stocks, including Mag 7 stocks and a few others. It’s independent research and has helped us completely ignore the bearish and biased media. They’re interested in viewership and clicks and will scare the heck out of everyone to achieve their own selfish, money-making goals. EarningsBeats.com is interested in helping folks navigate a landscape designed to misinform and mislead. We’re interested in making money, that’s it. Follow the charts, not the headlines.
NASDAQ 100
The AD line exploded higher on the NASDAQ 100, mostly because Mag 7 stocks were heavily accumulated during the early-April massacre. The same thing occurred in March 2020 during the pandemic, prior to these stocks skyrocketing later in 2020. Then we saw a repeat in 2022, before a massive explosion higher in 2023. Once again, we’re seeing Wall Street’s “rinse and repeat” strategy of effectively stealing shares from unsuspecting retail traders. And once again, these stocks have been flying again.
It’s up to us to learn these lessons and not make the same mistakes over and over again during cyclical bear markets. At EarningsBeats.com, we take advantage of these selloffs before they occur. First, we move to cash. Next, we watch the stocks tumble. Third, we buy back in much cheaper at the same time that Wall Street does. Doesn’t this sound like a much better strategy? Follow what Wall Street is buying, not what they’re saying.
This manipulation applies to an even greater extent to individual stocks. One of my favorite stocks has been ridiculously-manipulated in 2025. Over the past four trading days, while the S&P 500 has been under pressure, this stock has gapped down 3.13, but has moved 8 bucks higher during the trading day. It’s one of our 12 individual stocks that we track each week and showed the most manipulation last week. Its AD line is soaring again and its relative strength vs. its industry peers has exploded higher since the first week of March. Owning stocks like this help us significantly outperform the S&P 500.
I’m featuring this stock in our FREE EB Digest newsletter on Tuesday morning. To register for our newsletter and receive this stock Tuesday morning before the market opens, simply CLICK HERE and provide your name and email address. Again, it’s free, there’s no credit card required, and you may unsubscribe at any time.
We run specials from time to time to allow new members an opportunity to enjoy our service for a year at a major discount. We started our annual Spring Special this past week and it runs through Monday at midnight. If you’d like to change your approach to the stock market and be more proactive, please consider taking advantage of this special. For more information and to Start Your Annual Membership Today, follow this link.
Happy trading!
Tom
Nordic Resources (NNL:AU) has announced A$3.5M Institutional Placement and New Chairman Appointed
Download the PDF here.
Kaiser Reef Limited (“Kaiser”, or “the Company”) (ASX:KAU) is pleased to announce that the first 10 days of ownership of the Henty Gold Mine has progressed to plan and the operation continues to bed in under Kaiser ownership.
Highlights
The first gold pour under Kaiser’s ownership has likely exceeded 1,200oz of gold, and is currently in transit to the Perth Mint for refining and outturn.
The acquisition of the Henty Gold Mine has positioned Kaiser as a multi-asset gold producer with significant growth potential.
Brad Valiukas, Kaiser’s executive Director – Operations commented:
“It’s been an excellent start for Kaiser at Henty, the team is transitioning well, and operational performance has been excellent. We are well positioned to build on the success that Catalyst has had at Henty, as it becomes our flagship asset. Kaiser is now a significantly stronger Company with the incorporation of Henty, and we look forward to advancing our assets and the Company.”
Key highlights of the Henty Gold Mine include:
For further information in respect to the acquisition, please refer to the Company’s ASX Announcement dated 24 March 2025.
Click here for the full ASX Release
After a very strong move in the week before this one, the markets chose to take a breather. They moved in a wide range but ended the week on a mildly negative note after rebounding from their low point of the week. While defending the key levels, the markets largely chose to stay within a defined range. The trading range remained reasonably wide; the Nifty oscillated in a 600.55-point range over the past five sessions. The volatility inched modestly higher; the India Vix rose 4.40% to 17.28 on a weekly basis. While keeping its head above crucial levels, the headline index closed with a net weekly loss of 166.65 points (-0.67).
The coming week will be an expiry week; we will have monthly derivatives expiry playing out as well. Going by the options data, the Nifty has created a trading range between 25100 and 24500 levels. The markets are likely to consolidate in this 600-point trading range. A directional bias would emerge only if the Nifty takes out 25100 on the upside convincingly or ends up violating the 24500 level. While the underlying trend stays intact, the markets are unlikely to develop any sustainable trend so long as they do not move past the 25100 level. While the markets stay in the defined range, it would be prudent to vigilantly guard profits at higher levels and rotate sectors effectively to remain invested in the relatively stronger pockets.
The weekly RSI is at 60.14; it stays neutral and does not show any divergence against the price. The weekly MACD is bullish and stays above its signal line.
The pattern analysis shows that the Nifty has formed a trading range between 25100 on the higher side and 24500 on the lower side. This means that a directional bias would emerge only if Nifty moves past 25100 convincingly or violates the 24500 level. Until either of these two things happens, we will see the Nifty consolidating in this defined range. The Nifty has so far defended the pattern support level that also exists in the 24400-24500 zone.
Overall, the markets continue to remain in a challenging environment and face strong resistance near the 25100 level. So long as the Nifty stays below this level, it stays prone to corrective spikes, which may also keep volatility at slightly elevated levels as well. Given the current technical structure, it would be imperative that not only the sectors be rotated properly to stay invested in relatively stronger pockets, but all existing gains must also be vigilantly guarded at current levels by the investors. While continuing to keep leveraged exposures at modest levels, a cautious outlook is advised for the coming week.
In our look at Relative Rotation Graphs®, we compared various sectors against the CNX500 (NIFTY 500 Index), representing over 95% of the free-float market cap of all the listed stocks.
Relative Rotation Graphs (RRG) show that while the Nifty Consumption, PSU Bank, Infrastructure, Banknifty, FMCG, and Commodities indices are in the leading quadrant, all are showing a distinct slowdown in their relative momentum against the broader Nifty 500 Index. While these groups are likely to show resilience and may relatively outperform, except for the Consumption Index, they are giving up in favor of other sectors that are showing renewed relative strength.
The Nifty Financial Services Index has rolled inside the weakening quadrant. The Nifty Metal and Services Sector Indices are also inside the weakening quadrant.
While the Nifty Pharma Index continues to languish inside the lagging quadrant, the IT Index, which is also inside the lagging quadrant, is showing sharp improvement in its relative momentum against the broader markets.
The Nifty Realty, Auto, Midcap 100, and Energy Sector Indices are inside the improving quadrant. These groups are expected to continue bettering their relative performance against the broader markets.
Important Note: RRG charts show the relative strength and momentum of a group of stocks. In the above Chart, they show relative performance against NIFTY500 Index (Broader Markets) and should not be used directly as buy or sell signals.
Milan Vaishnav, CMT, MSTA
Consulting Technical Analyst